tiprankstipranks
Advertisement
Advertisement

AZN Stock Latest News

Why I’m Bullish on IONQ after the Selloff
Market NewsWhy I’m Bullish on IONQ after the Selloff
13m ago
AZN
ENRD
AstraZeneca Shuts Down China NASH Registry: What It Means for AZN Investors
PremiumCompany Announcements
AstraZeneca Shuts Down China NASH Registry: What It Means for AZN Investors
21h ago
AZN
AstraZeneca Earnings Call: Oncology Strength Amid Setbacks
PremiumCompany Announcements
AstraZeneca Earnings Call: Oncology Strength Amid Setbacks
2d ago
AZN
AstraZeneca’s AZD2389 Liver Fibrosis Study Reaches Key Early Milestone
PremiumCompany Announcements
AstraZeneca’s AZD2389 Liver Fibrosis Study Reaches Key Early Milestone
3d ago
AZN
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
PremiumThe Fly
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
3d ago
F
GM
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
PremiumThe FlyAstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
3d ago
AZN
OMER
Omeros up 11% to $10.89 after AstraZeneca study failure
Premium
The Fly
Omeros up 11% to $10.89 after AstraZeneca study failure
3d ago
AZN
OMER
Morning Movers: Ensign Group surges following second quarter results
Premium
The Fly
Morning Movers: Ensign Group surges following second quarter results
3d ago
AMR
AZN
AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint
PremiumThe Fly
AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint
3d ago
AZN
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint
PremiumThe Fly
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint
3d ago
AZN
AstraZeneca reports Sone-Ve improved survival in gastric cancers
PremiumThe Fly
AstraZeneca reports Sone-Ve improved survival in gastric cancers
3d ago
AZN
AstraZeneca: Buy Rating Reiterated as Strong Q2, Robust Pipeline Support Unchanged 16,500 GBp Price Target
PremiumRatings
AstraZeneca: Buy Rating Reiterated as Strong Q2, Robust Pipeline Support Unchanged 16,500 GBp Price Target
3d ago
AZN
AstraZeneca reaffirms FY26 revenue, core EPS guidance
PremiumThe FlyAstraZeneca reaffirms FY26 revenue, core EPS guidance
3d ago
AZN
AstraZeneca ‘on track’ to deliver ambition of $80B in revenue in 2030
Premium
The Fly
AstraZeneca ‘on track’ to deliver ambition of $80B in revenue in 2030
3d ago
AZN
AstraZeneca reports Q2 core EPS $2.63, up 18% at CER
Premium
The Fly
AstraZeneca reports Q2 core EPS $2.63, up 18% at CER
3d ago
AZN
AstraZeneca raises interim dividend to $1.06 per share
PremiumThe Fly
AstraZeneca raises interim dividend to $1.06 per share
3d ago
AZN
AstraZeneca’s Alexion Reports Mixed Ultomiris Trial Results in HSCT‑TMA, Advances Paediatric Filings
PremiumCompany Announcements
AstraZeneca’s Alexion Reports Mixed Ultomiris Trial Results in HSCT‑TMA, Advances Paediatric Filings
3d ago
AZN
AstraZeneca’s Sone-Ve delivers pivotal survival benefit in CLDN18.2-positive gastric cancer
PremiumCompany Announcements
AstraZeneca’s Sone-Ve delivers pivotal survival benefit in CLDN18.2-positive gastric cancer
3d ago
AZN
AstraZeneca Delivers Solid H1 Growth and Bolsters Pipeline with Strategic Deals
PremiumCompany Announcements
AstraZeneca Delivers Solid H1 Growth and Bolsters Pipeline with Strategic Deals
3d ago
AZN
MIRANDA Trial Completion: AstraZeneca’s Tozorakimab Targets High-Risk COPD Market
PremiumCompany AnnouncementsMIRANDA Trial Completion: AstraZeneca’s Tozorakimab Targets High-Risk COPD Market
6d ago
AZN
AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.
Premium
Market News
AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.
6d ago
AZN
AstraZeneca, Daiichi’s Enhertu with pertuzumab recommended for approval in EU
Premium
The Fly
AstraZeneca, Daiichi’s Enhertu with pertuzumab recommended for approval in EU
6d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >